GlassScriptPhysician profile
Dawn D Gammon
NPI 1659379345
$4,177.55
in general payments reported to CMS, 2019-2025
19 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $33.26 · 2021: $221 · 2022: $766 · 2023: $2,137 · 2024: $513 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781 · Travel and Lodging: $1,119 · Entertainment: $133 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.20 |
| Travel and Lodging | $1,119.08 |
| Entertainment | $133.14 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,668.34 | 2019-2025 | Air Optix, Dailies Aqua Comfort Plus, Dailies Total1 Multifocal |
| Bausch & Lomb Americas INC. | $190.03 | 2024-2025 | Infuse, Xiidra, Miebo |
| Optos, INC. | $166.40 | 2020-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Johnson & Johnson Vision Care, INC. | $152.29 | 2022 | |
| Sun Pharmaceutical Industries INC. | $144.84 | 2023-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $100.00 | 2021 | |
| Maculogix, INC. | $97.58 | 2021 | |
| Heru, INC. | $93.89 | 2022 | |
| Biotissue Holdings INC. | $92.31 | 2024 | |
| Rxsight INC | $78.39 | 2022 | |
| Coopervision INC. | $72.33 | 2022-2025 | Misight Contact Lens, Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $71.37 | 2022 | |
| Abbvie INC. | $68.98 | 2022-2025 | |
| Dompe US, INC. | $54.43 | 2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $43.65 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $36.57 | 2024 | Xdemvy |
| Oasis Medical, INC. | $16.00 | 2023 | Oasis Tears |
| Oyster Point Pharma, INC. | $15.17 | 2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Gammon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.